Source:http://linkedlifedata.com/resource/pubmed/id/11018857
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0019682,
umls-concept:C0019699,
umls-concept:C0032105,
umls-concept:C0332307,
umls-concept:C0441889,
umls-concept:C0681850,
umls-concept:C0887947,
umls-concept:C1539477,
umls-concept:C1550501,
umls-concept:C1706203,
umls-concept:C1749467,
umls-concept:C1882115,
umls-concept:C2349001,
umls-concept:C2697811
|
pubmed:issue |
14
|
pubmed:dateCreated |
2001-1-4
|
pubmed:abstractText |
Plasma levels of soluble Fas (sFas) are elevated in human immunodeficiency virus type 1 (HIV-1) infection, indicating dysregulation of the Fas apoptosis pathway and chronic immune activation. We performed a retrospective study to investigate the effects of HAART on plasma levels of sFas. A cross-sectional study of 27 drug-naive infected subjects and 49 patients under antiretroviral treatment showed that plasma levels of sFas were higher in HIV-1-infected subjects than in 52 HIV-1-negative controls, independently of the treatment status. In a longitudinal study of 69 patients undergoing HAART, we observed a minimal, but significant decrease in sFas plasma levels after 1 year of therapy. Levels of sFas, however, remained still higher than physiologic values. Patients undergoing HAART were further classified as nonresponders or responders on the basis of viremia suppression; no significant changes in plasma levels of sFas were observed between the two groups. These findings show that 1 year of HAART has a minor effect on the sFas levels in plasma. Long-term HAART may be required to normalize the dysregulation of the Fas apoptotic pathway and the persistent immune activation initiated by HIV-1.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0889-2229
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
20
|
pubmed:volume |
16
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1379-84
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11018857-Anti-HIV Agents,
pubmed-meshheading:11018857-Antigens, CD95,
pubmed-meshheading:11018857-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:11018857-CD4 Lymphocyte Count,
pubmed-meshheading:11018857-Cross-Sectional Studies,
pubmed-meshheading:11018857-HIV Infections,
pubmed-meshheading:11018857-HIV-1,
pubmed-meshheading:11018857-Humans,
pubmed-meshheading:11018857-Longitudinal Studies,
pubmed-meshheading:11018857-Matched-Pair Analysis,
pubmed-meshheading:11018857-RNA, Viral,
pubmed-meshheading:11018857-Retrospective Studies,
pubmed-meshheading:11018857-Reverse Transcriptase Inhibitors,
pubmed-meshheading:11018857-Time Factors,
pubmed-meshheading:11018857-Viremia,
pubmed-meshheading:11018857-Virus Replication
|
pubmed:year |
2000
|
pubmed:articleTitle |
High plasma levels of soluble fas in HIV type 1-infected subjects are not normalized during highly active antiretroviral therapy.
|
pubmed:affiliation |
Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|